Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Sondak, VK
   Adjuvant therapy for melanoma
   CANCER JOURNAL
   
   V.K. Sondak, "Adjuvant therapy for melanoma", CANCER J, 7, 2001, pp. S24-S27
2. Lao, YH
   Endogenous angiogenesis inhibitors and their therapeutic implications
   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
   
   Y.H. Lao, "Endogenous angiogenesis inhibitors and their therapeutic implications", INT J BIO C, 33(4), 2001, pp. 357-369
3. Altucci, L; Rossin, A; Raffelsberger, W; Reitmair, A; Chomienne, C; Gronemeyer, H
   Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrineaction of tumor-selective death ligand TRAIL
   NATURE MEDICINE
   
   L. Altucci et al., "Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrineaction of tumor-selective death ligand TRAIL", NAT MED, 7(6), 2001, pp. 680-686
4. Nichols, JC; Ince, A; Akduman, L; Mann, ES
   Interferon-alpha 2a treatment of neuro-Behcet disease
   JOURNAL OF NEURO-OPHTHALMOLOGY
   
   J.C. Nichols et al., "Interferon-alpha 2a treatment of neuro-Behcet disease", J NEURO-OPH, 21(2), 2001, pp. 109-111
5. Godley, PA; Taylor, M
   Renal cell carcinoma
   CURRENT OPINION IN ONCOLOGY
   
   P.A. Godley e M. Taylor, "Renal cell carcinoma", CURR OPIN O, 13(3), 2001, pp. 199-203
6. Lafuma, A; Dreno, B; Delaunay, M; Emery, C; Fagnani, F; Hieke, K; Bonerandi, JJ; Grob, JJ
   Economic analysis of adjuvant therapy with interferon alpha-2a in stage IImalignant melanoma
   EUROPEAN JOURNAL OF CANCER
   
   A. Lafuma et al., "Economic analysis of adjuvant therapy with interferon alpha-2a in stage IImalignant melanoma", EUR J CANC, 37(3), 2001, pp. 369-375
7. Metintas, M; Metintas, S; Ucgun, I; Gibbs, AR; Harmanci, E; Alatas, F; Erginel, S; Tel, N; Pasaoglu, O
   Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics
   RESPIRATORY MEDICINE
   
   M. Metintas et al., "Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics", RESP MED, 95(10), 2001, pp. 829-835
8. Wu, HL; Ramachandran, C; Bielinska, AU; Kingzett, K; Sun, R; Weiner, ND; Roessler, BJ
   Topical transfection using plasmid DNA in a water-in-oil nanoemulsion
   INTERNATIONAL JOURNAL OF PHARMACEUTICS
   
   H.L. Wu et al., "Topical transfection using plasmid DNA in a water-in-oil nanoemulsion", INT J PHARM, 221(1-2), 2001, pp. 23-34
9. Grem, JL; Quinn, M; Ismail, AS; Takimoto, CH; Lush, R; Liewehr, DJ; Steinberg, SM; Balis, FM; Chen, AP; Monahan, BP; Harold, N; Corse, W; Pang, J; Murphy, RF; Allegra, CJ; Hamilton, JM
   Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   J.L. Grem et al., "Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion", CANC CHEMOT, 47(2), 2001, pp. 117-125
10. Sabatelli, M; Madia, F; Mignogna, T; Lippi, G; Quaranta, L; Tonali, P
    Pure motor chronic inflammatory demyelinating polyneuropathy
    JOURNAL OF NEUROLOGY
    
    M. Sabatelli et al., "Pure motor chronic inflammatory demyelinating polyneuropathy", J NEUROL, 248(9), 2001, pp. 772-777
11. Eggermont, AMM
    Frontiers in adjuvant therapy in stage II-III melanoma
    TUMORI
    
    A.M.M. Eggermont, "Frontiers in adjuvant therapy in stage II-III melanoma", TUMORI, 87(4), 2001, pp. S60-S63
12. Hadziyannis, AS; Papaioannou, C; Spanou, F; Manesis, EK; Hadziyannis, SJ
    Induction interferon therapy in nave patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    
    A.S. Hadziyannis et al., "Induction interferon therapy in nave patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit", ALIM PHARM, 15(4), 2001, pp. 551-557
13. Vogelzang, NJ; Aklilu, M; Stadler, WM; Dumas, MC; Mikulski, SM
    A phase II trial of weekly intravenous ranpirnase (Onconase (R)), a novel ribonuclease in patients with metastatic kidney cancer
    INVESTIGATIONAL NEW DRUGS
    
    N.J. Vogelzang et al., "A phase II trial of weekly intravenous ranpirnase (Onconase (R)), a novel ribonuclease in patients with metastatic kidney cancer", INV NEW DR, 19(3), 2001, pp. 255-260
14. Saperstein, DS; Katz, JS; Amato, AA; Barohn, RJ
    Clinical spectrum of chronic acquired demyelinating polyneuropathies
    MUSCLE & NERVE
    
    D.S. Saperstein et al., "Clinical spectrum of chronic acquired demyelinating polyneuropathies", MUSCLE NERV, 24(3), 2001, pp. 311-324
15. Tannock, IF
    Removing the primary tumor after the cancer has spread
    NEW ENGLAND JOURNAL OF MEDICINE
    
    I.F. Tannock, "Removing the primary tumor after the cancer has spread", N ENG J MED, 345(23), 2001, pp. 1699-1700
16. Madrona, AP; Escribano, JM; Ruiz, FN; Barba, EM; Jordana, MC; Gonzalez, JMR; Pedreno, PS; Fernandez, JLN; Iniesta, JF; Lopez, JB; Paricio, PP
    Sentinel node biopsy in melanoma using preoperative lymphoscintigraphy andintraoperative handheld gamma probe
    MEDICINA CLINICA
    
    A.P. Madrona et al., "Sentinel node biopsy in melanoma using preoperative lymphoscintigraphy andintraoperative handheld gamma probe", MED CLIN, 117(13), 2001, pp. 481-486
17. Menetrier-Caux, C; Thomachot, MC; Alberti, L; Montmain, G; Blay, JY
    IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells
    CANCER RESEARCH
    
    C. Menetrier-Caux et al., "IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells", CANCER RES, 61(7), 2001, pp. 3096-3104
18. Hall, GW
    Kasabach-Merritt syndrome: Pathogenesis and management
    BRITISH JOURNAL OF HAEMATOLOGY
    
    G.W. Hall, "Kasabach-Merritt syndrome: Pathogenesis and management", BR J HAEM, 112(4), 2001, pp. 851-862
19. Blaheta, HJ; Paul, T; Sotlar, K; Maczey, E; Schittek, B; Paul, A; Moehrle, M; Breuninger, H; Bueltmann, B; Rassner, G; Garbe, C
    Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness
    BRITISH JOURNAL OF DERMATOLOGY
    
    H.J. Blaheta et al., "Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness", BR J DERM, 145(2), 2001, pp. 195-202
20. Brownbridge, GG; Gold, J; Edward, M; MacKie, RM
    Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma
    BRITISH JOURNAL OF DERMATOLOGY
    
    G.G. Brownbridge et al., "Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma", BR J DERM, 144(2), 2001, pp. 279-287
21. Yu, Y; Varughese, J; Brown, LF; Mulliken, JB; Bischoff, J
    Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells
    AMERICAN JOURNAL OF PATHOLOGY
    
    Y. Yu et al., "Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells", AM J PATH, 159(6), 2001, pp. 2271-2280
22. Hauschild, A; Lischner, S; Christophers, E
    Surgical and systemic adjuvant treatment of head and neck primary melanoma.
    LARYNGO-RHINO-OTOLOGIE
    
    A. Hauschild et al., "Surgical and systemic adjuvant treatment of head and neck primary melanoma.", LARY RH OTO, 79(7), 2000, pp. 428-433
23. Royce, ME; Hoff, PM; Pazdur, R
    Progress in colorectal cancer chemotherapy - How far have we come, how farto go?
    DRUGS & AGING
    
    M.E. Royce et al., "Progress in colorectal cancer chemotherapy - How far have we come, how farto go?", DRUG AGING, 17(3), 2000, pp. 201-216
24. Bajetta, E; Bichisao, E; Artale, S; Celio, L; Ferrari, L; Di Bartolomeo, M; Zilembo, N; Stani, SC; Buzzoni, R
    New clinical trials for the treatment of neuroendocrine tumors
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE
    
    E. Bajetta et al., "New clinical trials for the treatment of neuroendocrine tumors", Q J NUCL M, 44(1), 2000, pp. 96-101
25. Paller, AS
    Responses to anti-angiogenic therapies
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS
    
    A.S. Paller, "Responses to anti-angiogenic therapies", J INV D SYM, 5(1), 2000, pp. 83-86
26. Wu, K; Kim, HT; Rodriquez, JL; Munoz-Medellin, D; Mohsin, SK; Hilsenbeck, SG; Lamph, WW; Gottardis, MM; Shirley, MA; Kuhn, JG; Green, JE; Brown, PH
    9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus40 T antigen-transgenic mice
    CLINICAL CANCER RESEARCH
    
    K. Wu et al., "9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus40 T antigen-transgenic mice", CLIN CANC R, 6(9), 2000, pp. 3696-3704
27. Lee, ML; Tomsu, K; Von Eschen, KB
    Duration of survival for disseminated malignant melanoma: results of a meta-analysis
    MELANOMA RESEARCH
    
    M.L. Lee et al., "Duration of survival for disseminated malignant melanoma: results of a meta-analysis", MELANOMA RE, 10(1), 2000, pp. 81-92
28. Schoffski, P; Ganser, A; Pascheberg, U; Busche, G; Gaede, B; Hertenstein, B
    Complete haematological and cytogenetic response to interferon alpha-2a ofa myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration
    ANNALS OF HEMATOLOGY
    
    P. Schoffski et al., "Complete haematological and cytogenetic response to interferon alpha-2a ofa myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration", ANN HEMATOL, 79(2), 2000, pp. 95-98
29. Yao, GB; Fu, XX; Tian, GS; Xu, DZ; Hao, LJ; Huangfu, YS; Su, CX
    A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
    
    G.B. Yao et al., "A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection", J GASTR HEP, 15(10), 2000, pp. 1165-1170
30. Motzer, RJ; Mazumdar, M; Bacik, J; Russo, P; Berg, WJ; Metz, EM
    Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    R.J. Motzer et al., "Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma", J CL ONCOL, 18(9), 2000, pp. 1928-1935
31. Vasey, PA
    Immunotherapy for renal carcinoma: theoretical basis and current standard of care
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    P.A. Vasey, "Immunotherapy for renal carcinoma: theoretical basis and current standard of care", BR J CL PH, 50(6), 2000, pp. 521-529
32. Koshy, A; Marcellin, P; Martinot, M; Madda, JP
    Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis
    LIVER
    
    A. Koshy et al., "Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis", LIVER, 20(4), 2000, pp. 335-339
33. Amato, RJ
    Chemotherapy for renal cell carcinoma
    SEMINARS IN ONCOLOGY
    
    R.J. Amato, "Chemotherapy for renal cell carcinoma", SEMIN ONCOL, 27(2), 2000, pp. 177-186
34. Coldiron, BM
    Sentinel node biopsy: who needs it?
    INTERNATIONAL JOURNAL OF DERMATOLOGY
    
    B.M. Coldiron, "Sentinel node biopsy: who needs it?", INT J DERM, 39(11), 2000, pp. 807-811
35. Blay, JY; Thomachot, MC; Alberti, L; Bachelot, T; Voorzanger-Rousselot, N; Puisieux, I; Odin, L; Menetrier-Caux, C
    Immunotherapy of cancers - New approaches
    BULLETIN DU CANCER
    
    J.Y. Blay et al., "Immunotherapy of cancers - New approaches", B CANCER, 87(1), 2000, pp. 97-106
36. Hauschild, A; Volkenandt, M; Garbe, C
    Adjuvant drug treatment of malignant melanoma
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    
    A. Hauschild et al., "Adjuvant drug treatment of malignant melanoma", DEUT MED WO, 125(42), 2000, pp. 1272-1278
37. Piattelli, A; Fioroni, M; Santinelli, A; Rubini, C
    bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study
    ORAL ONCOLOGY
    
    A. Piattelli et al., "bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study", ORAL ONCOL, 35(3), 1999, pp. 314-320
38. Ravandi, F; Rytting, ME; Osmon, C; Braud, EL; Roach, RW; Edwards, K; Winn, R; Abbruzzese, JL; Pazdur, R
    Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer
    ANTI-CANCER DRUGS
    
    F. Ravandi et al., "Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer", ANTI-CANC D, 10(6), 1999, pp. 519-524
39. Zuetenhorst, H; Taal, BG; Boot, H; Olmos, RV; Hoefnagel, G
    Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBC): pharmacological MIBG, I-131-labelled MIBG and the combination
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
    
    H. Zuetenhorst et al., "Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBC): pharmacological MIBG, I-131-labelled MIBG and the combination", EUR J GASTR, 11(10), 1999, pp. 1157-1164
40. Nakashima, T; Masuda, M; Matsui, K; Inokuchi, A; Kuraoka, A; Komiyama, S
    Induction of apoptosis in maxillary sinus cancer cells by 5-fluorouracil, vitamin A and radiation (FAR) therapy
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
    
    T. Nakashima et al., "Induction of apoptosis in maxillary sinus cancer cells by 5-fluorouracil, vitamin A and radiation (FAR) therapy", EUR ARCH OT, 256, 1999, pp. S64-S69
41. Kornek, G; Reiner, A; Sagaster, P; Stierer, M; Mayer, A; Ludwig, H
    Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer
    CANCER INVESTIGATION
    
    G. Kornek et al., "Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer", CANCER INV, 17(3), 1999, pp. 189-194
42. Mross, K; Scheulen, ME; Manegold, C; Westerhausen, M; Edler, L; Becher, R
    Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma - A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society
    ONKOLOGIE
    
    K. Mross et al., "Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma - A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society", ONKOLOGIE, 22(5), 1999, pp. 412-415
43. Parthasarathy, R; Gilbert, B; Mehta, K
    Aerosol delivery of liposomal all-trans-retinoic acid to the lungs
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    R. Parthasarathy et al., "Aerosol delivery of liposomal all-trans-retinoic acid to the lungs", CANC CHEMOT, 43(4), 1999, pp. 277-283
44. Damle, S; Beitler, JJ; Haynes, H; Camacho, M; Wolf, E; Wadler, S
    Phase I-II study of 5-fluorouracil, recombinant interferon alpha 2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    S. Damle et al., "Phase I-II study of 5-fluorouracil, recombinant interferon alpha 2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus", AM J CL ONC, 22(4), 1999, pp. 391-395
45. Gurer, US; Palanduz, S; Cevikbas, A; Derici, K; Johansson, C; Ozturk, S
    Effect of cefodizime, ofloxacin, ciprofloxacin and interferon alpha-2a, alone and in combination, on phagocytic and candidacidal functions of leucocytes from patients with chronic renal failure
    MEDICAL SCIENCE RESEARCH
    
    U.S. Gurer et al., "Effect of cefodizime, ofloxacin, ciprofloxacin and interferon alpha-2a, alone and in combination, on phagocytic and candidacidal functions of leucocytes from patients with chronic renal failure", MED SCI RES, 27(5), 1999, pp. 315-318
46. Ychou, M; Duffour, J; Pinguet, F; Kramar, A; Joulia, JM; Topart, D; Bressolle, F
    Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: A feasibility study in patients with advanced colorectal cancer
    ANTICANCER RESEARCH
    
    M. Ychou et al., "Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: A feasibility study in patients with advanced colorectal cancer", ANTICANC R, 19(3B), 1999, pp. 2229-2235
47. Wollina, U; Hahnfeld, S; Kosmehl, H
    Primary cutaneous marginal center lymphoma - complete remission induced byinterferon alpha 2a
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    
    U. Wollina et al., "Primary cutaneous marginal center lymphoma - complete remission induced byinterferon alpha 2a", J CANC RES, 125(5), 1999, pp. 305-308
48. DiPaola, RS
    Approaches to the treatment of patients with hormone-sensitive prostate cancer
    SEMINARS IN ONCOLOGY
    
    R.S. DiPaola, "Approaches to the treatment of patients with hormone-sensitive prostate cancer", SEMIN ONCOL, 26(5), 1999, pp. 24-27
49. DiPaola, RS; Aisner, J
    Overcoming bcl-2- and p53-mediated resistance in prostate cancer
    SEMINARS IN ONCOLOGY
    
    R.S. DiPaola e J. Aisner, "Overcoming bcl-2- and p53-mediated resistance in prostate cancer", SEMIN ONCOL, 26(1), 1999, pp. 112-116
50. Bajetta, E; Ferrari, L; Martinetti, A; Celio, L; Procopio, G; Artale, S; Zilembo, N; Di Bartolomeo, M; Seregni, E; Bombardieri, E
    Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
    CANCER
    
    E. Bajetta et al., "Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors", CANCER, 86(5), 1999, pp. 858-865
51. Dorval, T; Negrier, S; Chevreau, C; Avril, MF; Baume, D; Cupissol, D; Oskam, R; de Peuter, R; Vinke, J; Herrera, L; Escudier, B
    Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma
    CANCER
    
    T. Dorval et al., "Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma", CANCER, 85(5), 1999, pp. 1060-1066
52. Hersey, P
    Advances in management of melanoma
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    
    P. Hersey, "Advances in management of melanoma", AUST NZ J M, 29(3), 1999, pp. 292-299
53. Krogsgaard, K
    The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B
    JOURNAL OF VIRAL HEPATITIS
    
    K. Krogsgaard, "The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B", J VIRAL HEP, 5(6), 1998, pp. 389-397
54. RECCHIA F; FRATI L; REA S; TORCHIO P; SICA G
    MINIMAL RESIDUAL DISEASE IN METASTATIC BREAST-CANCER - TREATMENT WITHIFN-BETA, RETINOIDS, AND TAMOXIFEN
    Journal of interferon & cytokine research
    
    F. Recchia et al., "MINIMAL RESIDUAL DISEASE IN METASTATIC BREAST-CANCER - TREATMENT WITHIFN-BETA, RETINOIDS, AND TAMOXIFEN", Journal of interferon & cytokine research, 18(1), 1998, pp. 41-47
55. NASSIM M; ROUINI MR; CRIPPS MC; SHIRAZI FH; VEERASINGHAN S; MOLEPO JM; OBROCEA M; REDMOND D; BATES S; FRY D; STEWART DJ; GOEL R
    EFFECTS OF PALA ON THE PHARMACOKINETICS OF 5-FLUOROURACIL
    Oncology Reports
    
    M. Nassim et al., "EFFECTS OF PALA ON THE PHARMACOKINETICS OF 5-FLUOROURACIL", Oncology Reports, 5(1), 1998, pp. 217-221
56. PEREZ E; BARNADAS MA; GARCIAPATOS V; PEDRO C; CURELL R; SANDER CA; KIND P; DEMORAGAS JM; ALOMAR A
    KAPOSIS-SARCOMA IN A PATIENT WITH ERYTHROBLASTOPENIA AND THYMOMA - REACTIVATION AFTER TOPICAL CORTICOSTEROIDS
    Dermatology
    
    E. Perez et al., "KAPOSIS-SARCOMA IN A PATIENT WITH ERYTHROBLASTOPENIA AND THYMOMA - REACTIVATION AFTER TOPICAL CORTICOSTEROIDS", Dermatology, 197(3), 1998, pp. 264-267
57. CAMPOVOEGELI A; ESTRACH T; MARTI RM; COROMINAS N; TUSET M; MASCARO JM
    ACROCYANOSIS INDUCED BY INTERFERON ALPHA(2A)
    Dermatology
    
    A. Campovoegeli et al., "ACROCYANOSIS INDUCED BY INTERFERON ALPHA(2A)", Dermatology, 196(3), 1998, pp. 361-363
58. KIM J; ZHI JG; SATOH H; KOSSTWARDY SG; PASSE SM; PATEL IH; PAZDUR R
    PHARMACOKINETICS OF RECOMBINANT HUMAN INTERFERON-ALPHA-2A COMBINED WITH 5-FLUOROURACIL IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA
    Anti-cancer drugs
    
    J. Kim et al., "PHARMACOKINETICS OF RECOMBINANT HUMAN INTERFERON-ALPHA-2A COMBINED WITH 5-FLUOROURACIL IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA", Anti-cancer drugs, 9(8), 1998, pp. 689-696
59. JOZAN S; COURTADE M; MATHIEUBOUE A; LOCHON I; BUGAT R
    CYTOTOXIC EFFECT OF INTERFERON-ALPHA-2A IN COMBINATION WITH ALL-TRANS-RETINOIC ACID OR CISPLATIN IN HUMAN OVARIAN-CARCINOMA CELL-LINES
    Anti-cancer drugs
    
    S. Jozan et al., "CYTOTOXIC EFFECT OF INTERFERON-ALPHA-2A IN COMBINATION WITH ALL-TRANS-RETINOIC ACID OR CISPLATIN IN HUMAN OVARIAN-CARCINOMA CELL-LINES", Anti-cancer drugs, 9(3), 1998, pp. 229-238
60. Wright, SE; Hutcheson, DP; Cummins, JM
    Low dose oral interferon alpha 2a in HIV-1 seropositive patients: A double-blind, placebo-controlled trial
    BIOTHERAPY
    
    S.E. Wright et al., "Low dose oral interferon alpha 2a in HIV-1 seropositive patients: A double-blind, placebo-controlled trial", BIOTHERAPY, 11(4), 1998, pp. 229-234
61. Lanvers, C; Hempel, G; Blaschke, G; Boos, J
    Chemically induced isomerization and differential uptake modulate retinoicacid disposition in HL-60 cells
    FASEB JOURNAL
    
    C. Lanvers et al., "Chemically induced isomerization and differential uptake modulate retinoicacid disposition in HL-60 cells", FASEB J, 12(15), 1998, pp. 1627-1633
62. PARK TK; LEE JP; KIM SN; CHOI SM; KUDELKA AP; KAVANAGH JJ
    INTERFERON-ALPHA-2A, 13-CIS-RETINOIC ACID AND RADIOTHERAPY FOR LOCALLY ADVANCED-CARCINOMA OF THE CERVIX - A PILOT-STUDY
    European journal of gynaecological oncology
    
    T.K. Park et al., "INTERFERON-ALPHA-2A, 13-CIS-RETINOIC ACID AND RADIOTHERAPY FOR LOCALLY ADVANCED-CARCINOMA OF THE CERVIX - A PILOT-STUDY", European journal of gynaecological oncology, 19(1), 1998, pp. 35-38
63. RYU S; KIM OB; KIM SH; HE SQ; KIM JH
    IN-VITRO RADIOSENSITIZATION OF HUMAN CERVICAL-CARCINOMA CELLS BY COMBINED USE OF 13-CIS-RETINOIC ACID AND INTERFERON-ALPHA-2A
    International journal of radiation oncology, biology, physics
    
    S. Ryu et al., "IN-VITRO RADIOSENSITIZATION OF HUMAN CERVICAL-CARCINOMA CELLS BY COMBINED USE OF 13-CIS-RETINOIC ACID AND INTERFERON-ALPHA-2A", International journal of radiation oncology, biology, physics, 41(4), 1998, pp. 869-873
64. Parthasarathy, R; Mehta, K
    Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form
    CANCER LETTERS
    
    R. Parthasarathy e K. Mehta, "Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form", CANCER LETT, 134(2), 1998, pp. 121-128
65. TRYFONAS GI; TSIKOPOULOS G; LIASIDOU E; GAVOPOULOS S; GEORGAKIS G; BADOURAKI M; SOULTANIDES C
    CONSERVATIVE TREATMENT OF HEMANGIOMAS IN INFANCY AND CHILDHOOD WITH INTERFERON-ALPHA 2A
    Pediatric surgery international
    
    G.I. Tryfonas et al., "CONSERVATIVE TREATMENT OF HEMANGIOMAS IN INFANCY AND CHILDHOOD WITH INTERFERON-ALPHA 2A", Pediatric surgery international, 13(8), 1998, pp. 590-593
66. PALMERI S; MELI M; DANOVA M; BERNARDO G; LEONARDI V; DASTOLI G; RAUSA L; RUSSO A; FILIPELLI G; PALMIERI G; RUSSO A; SCARPATI MD; LORUSSO V; DILAURO L; COLUCCI G; BRUNI G; PIAZZI M; GEBBIA N; SPADA S
    5-FLUOROURACIL PLUS INTERFERON ALPHA-2A COMPARED TO 5-FLUOROURACIL ALONE IN THE TREATMENT OF ADVANCED COLON-CARCINOMA - A MULTICENTRIC RANDOMIZED STUDY
    Journal of cancer research and clinical oncology
    
    S. Palmeri et al., "5-FLUOROURACIL PLUS INTERFERON ALPHA-2A COMPARED TO 5-FLUOROURACIL ALONE IN THE TREATMENT OF ADVANCED COLON-CARCINOMA - A MULTICENTRIC RANDOMIZED STUDY", Journal of cancer research and clinical oncology, 124(3-4), 1998, pp. 191-198
67. WOLLINA U
    COMPLETE RESPONSE OF A PRIMARY CUTANEOUS T-CELL-RICH B-CELL LYMPHOMA TREATED WITH INTERFERON ALPHA-2A
    Journal of cancer research and clinical oncology
    
    U. Wollina, "COMPLETE RESPONSE OF A PRIMARY CUTANEOUS T-CELL-RICH B-CELL LYMPHOMA TREATED WITH INTERFERON ALPHA-2A", Journal of cancer research and clinical oncology, 124(2), 1998, pp. 127-129
68. Purohit, A; Moreau, L; Dietemann, A; Seibert, R; Pauli, G; Wihlm, JM; Quoix, E
    Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma
    LUNG CANCER
    
    A. Purohit et al., "Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma", LUNG CANC, 22(2), 1998, pp. 119-125
69. KWASNIEWSKA A; CHARZEWSKA J; TUKENDORF A; SEMCZUK M
    DIETARY FACTORS IN WOMEN WITH DYSPLASIA COLLI UTERI ASSOCIATED WITH HUMAN-PAPILLOMAVIRUS INFECTION
    Nutrition and cancer
    
    A. Kwasniewska et al., "DIETARY FACTORS IN WOMEN WITH DYSPLASIA COLLI UTERI ASSOCIATED WITH HUMAN-PAPILLOMAVIRUS INFECTION", Nutrition and cancer, 30(1), 1998, pp. 39-45
70. URABE T; KANEKO S; MATSUSHITA E; UNOURA M; KOBAYASHI K
    CLINICAL PILOT-STUDY OF INTRAHEPATIC ARTERIAL CHEMOTHERAPY WITH METHOTREXATE, 5-FLUOROURACIL, CISPLATIN AND SUBCUTANEOUS INTERFERON-ALPHA-2B FOR PATIENTS WITH LOCALLY ADVANCED HEPATOCELLULAR-CARCINOMA
    Oncology
    
    T. Urabe et al., "CLINICAL PILOT-STUDY OF INTRAHEPATIC ARTERIAL CHEMOTHERAPY WITH METHOTREXATE, 5-FLUOROURACIL, CISPLATIN AND SUBCUTANEOUS INTERFERON-ALPHA-2B FOR PATIENTS WITH LOCALLY ADVANCED HEPATOCELLULAR-CARCINOMA", Oncology, 55(1), 1998, pp. 39-47
71. BAFALOUKOS D; FOUNTZILAS G; SKARLOS D; PAVLIDIS N; BAKOYIANNIS C; KARVOUNIS N; KOSMIDIS P
    SUBCUTANEOUS LOW-DOSES OF INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA WITH CARBOPLATIN AND VINBLASTINE IN PATIENTS WITH ADVANCED MELANOMA
    Oncology
    
    D. Bafaloukos et al., "SUBCUTANEOUS LOW-DOSES OF INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA WITH CARBOPLATIN AND VINBLASTINE IN PATIENTS WITH ADVANCED MELANOMA", Oncology, 55(1), 1998, pp. 48-52
72. ELSTNER E; MULLER C; KOSHIZUKA K; WILLIAMSON EA; PARK D; ASOU H; SHINTAKU P; SAID JW; HEBER D; KOEFFLER HP
    LIGANDS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AND RETINOIC ACID RECEPTOR INHIBIT GROWTH AND INDUCE APOPTOSIS OF HUMAN BREAST-CANCER CELLS IN-VITRO AND IN BNX MICE
    Proceedings of the National Academy of Sciences of the United Statesof America
    
    E. Elstner et al., "LIGANDS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AND RETINOIC ACID RECEPTOR INHIBIT GROWTH AND INDUCE APOPTOSIS OF HUMAN BREAST-CANCER CELLS IN-VITRO AND IN BNX MICE", Proceedings of the National Academy of Sciences of the United Statesof America, 95(15), 1998, pp. 8806-8811
73. PERRY CM; WILDE MI
    INTERFERON-ALPHA-2A - A REVIEW OF ITS USE IN CHRONIC HEPATITIS-C
    Biodrugs
    
    C.M. Perry e M.I. Wilde, "INTERFERON-ALPHA-2A - A REVIEW OF ITS USE IN CHRONIC HEPATITIS-C", Biodrugs, 10(1), 1998, pp. 65-89
74. KIVISAKK P; ALM GV; TIAN WZ; MATUSEVICIUS D; FREDRIKSON S; LINK H
    NEUTRALIZING AND BINDING ANTI-INTERFERON-BETA-1B (IFN-BETA-1B) ANTIBODIES DURING IFN-BETA-1B TREATMENT OF MULTIPLE-SCLEROSIS
    Multiple sclerosis
    
    P. Kivisakk et al., "NEUTRALIZING AND BINDING ANTI-INTERFERON-BETA-1B (IFN-BETA-1B) ANTIBODIES DURING IFN-BETA-1B TREATMENT OF MULTIPLE-SCLEROSIS", Multiple sclerosis, 3(3), 1997, pp. 184-190
75. COOKSLEY WGE; MCIVOR C; WATSON K; SMITH B; JACKSON P; BROTODIHARDJO A; FARRELL GC; JONES DB; NGU M; MCCAUGHAN GW; OBRIEN E; KAVANAGH J; MORROW AW; DUDLEY F; CROMIE S; JENKINS P; HARLEY H; SHAW D; BATEY RG; CREWE E; BOWDEN S; LOCARNINI S; CUNNINGHAM A
    EFFICACY AND TOLERANCE OF A 6-MONTH TREATMENT COURSE OF DAILY INTERFERON-ALPHA-2A FOR CHRONIC HEPATITIS-C WITH CIRRHOSIS
    Journal of viral hepatitis
    
    W.G.E. Cooksley et al., "EFFICACY AND TOLERANCE OF A 6-MONTH TREATMENT COURSE OF DAILY INTERFERON-ALPHA-2A FOR CHRONIC HEPATITIS-C WITH CIRRHOSIS", Journal of viral hepatitis, 4(5), 1997, pp. 317-323
76. HUSSAIN M; GILL DS; LIAO MJ
    BOTH VARIANT FORMS OF INTERFERON-ALPHA-4 GENE (IFNA4A AND IFNA4B) AREPRESENT IN THE HUMAN-POPULATION
    Journal of interferon & cytokine research
    
    M. Hussain et al., "BOTH VARIANT FORMS OF INTERFERON-ALPHA-4 GENE (IFNA4A AND IFNA4B) AREPRESENT IN THE HUMAN-POPULATION", Journal of interferon & cytokine research, 17(9), 1997, pp. 559-566
77. WALPOLE ET; HERSEY P; THOMSON D; MCLEOD GRC
    RECOMBINANT INTERFERON-ALPHA-2A PLUS 5-FLUOROURACIL FOR THE TREATMENTOF METASTATIC MELANOMA
    Melanoma research
    
    E.T. Walpole et al., "RECOMBINANT INTERFERON-ALPHA-2A PLUS 5-FLUOROURACIL FOR THE TREATMENTOF METASTATIC MELANOMA", Melanoma research, 7(6), 1997, pp. 513-516
78. CHENG AL; CHUANG SF; SU IJ
    FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF RETINOIC ACIDS ONMALIGNANT-LYMPHOMAS
    Journal of the Formosan Medical Association
    
    A.L. Cheng et al., "FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF RETINOIC ACIDS ONMALIGNANT-LYMPHOMAS", Journal of the Formosan Medical Association, 96(7), 1997, pp. 525-534
79. OBERG K; ALM G
    THE INCIDENCE AND CLINICAL-SIGNIFICANCE OF ANTIBODIES TO INTERFERON-AIN PATIENTS WITH SOLID TUMORS
    Biotherapy
    
    K. Oberg e G. Alm, "THE INCIDENCE AND CLINICAL-SIGNIFICANCE OF ANTIBODIES TO INTERFERON-AIN PATIENTS WITH SOLID TUMORS", Biotherapy, 10(1), 1997, pp. 1-5
80. KHURI FR; KURIE JM; HONG WK
    CHEMOPREVENTION OF RESPIRATORY-TRACT CANCER
    Hematology/oncology clinics of North America
    
    F.R. Khuri et al., "CHEMOPREVENTION OF RESPIRATORY-TRACT CANCER", Hematology/oncology clinics of North America, 11(3), 1997, pp. 387
81. MILLER VA; BENEDETTI FM; RIGAS JR; VERRET AL; PFISTER DG; STRAUS D; KRIS MG; CRISP M; HEYMAN R; LOEWEN GR; TRUGLIA JA; WARRELL RP
    INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069
    Journal of clinical oncology
    
    V.A. Miller et al., "INITIAL CLINICAL-TRIAL OF A SELECTIVE RETINOID-X RECEPTOR-LIGAND, LGD1069", Journal of clinical oncology, 15(2), 1997, pp. 790-795
82. CARDAMAKIS E; RELAKIS K; GINOPOULOS P; KORANTZIS A; METALINOS K; STATHOPOULOS E; PAPATHANASIOU Z; MICHOPOULOS J; MANTOUVALOS H; KOTOULAS IG; TZINGOUNIS V
    TREATMENT OF PENILE INTRAEPITHELIAL NEOPLASIA (PIN) WITH INTERFERON ALPHA-2A, CO2-LASER (VAPORIZATION) AND 5-FLUOROURACIL 5-PERCENT (5-FU)
    European journal of gynaecological oncology
    
    E. Cardamakis et al., "TREATMENT OF PENILE INTRAEPITHELIAL NEOPLASIA (PIN) WITH INTERFERON ALPHA-2A, CO2-LASER (VAPORIZATION) AND 5-FLUOROURACIL 5-PERCENT (5-FU)", European journal of gynaecological oncology, 18(5), 1997, pp. 410-413
83. PERERA F; FISHER B; KOCHA W; PLEWES E; TAYLOR M; VINCENT M
    A PHASE-I PILOT-STUDY OF PELVIC RADIATION AND ALPHA-2A INTERFERON IN PATIENTS WITH LOCALLY ADVANCED OR RECURRENT RECTAL-CANCER
    International journal of radiation oncology, biology, physics
    
    F. Perera et al., "A PHASE-I PILOT-STUDY OF PELVIC RADIATION AND ALPHA-2A INTERFERON IN PATIENTS WITH LOCALLY ADVANCED OR RECURRENT RECTAL-CANCER", International journal of radiation oncology, biology, physics, 37(2), 1997, pp. 297-303
84. REGAZZI MB; IACONA I; GERVASUTTI C; LAZZARINO M; TOMA S
    CLINICAL PHARMACOKINETICS OF TRETINOIN
    Clinical pharmacokinetics
    
    M.B. Regazzi et al., "CLINICAL PHARMACOKINETICS OF TRETINOIN", Clinical pharmacokinetics, 32(5), 1997, pp. 382-402
85. LEE WM
    THERAPY OF HEPATITIS-C - INTERFERON ALFA-2A TRIALS
    Hepatology
    
    W.M. Lee, "THERAPY OF HEPATITIS-C - INTERFERON ALFA-2A TRIALS", Hepatology, 26(3), 1997, pp. 89-95
86. NAGLER A; NAGLER R; ACKERSTEIN A; LEVI S; MARMARY Y
    MAJOR SALIVARY-GLAND DYSFUNCTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES RECEIVING INTERLEUKIN-2-BASED IMMUNOTHERAPY POST-AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)
    Bone marrow transplantation
    
    A. Nagler et al., "MAJOR SALIVARY-GLAND DYSFUNCTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES RECEIVING INTERLEUKIN-2-BASED IMMUNOTHERAPY POST-AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)", Bone marrow transplantation, 20(7), 1997, pp. 575-580
87. DIPPOLD W; BERNHARD H; ZUMBUSCHENFELDE KHM
    CHEMOTHERAPY IN ADVANCED PANCREATIC-CANCER
    International journal of pancreatology
    
    W. Dippold et al., "CHEMOTHERAPY IN ADVANCED PANCREATIC-CANCER", International journal of pancreatology, 21(1), 1997, pp. 39-41
88. IMAI Y; KAWATA S; TAMURA S; ITO N; SEKI K; NISHIUCHI M; SHINJI Y; KIRIYAMA K; HIMENO S; MINAMI Y; KASHIHARA T; KAWAKAMI F; MAEDA H; YABUUCHI I; NISHIOKA M; SHIRAI Y; FUKUDA K; KISO S; ITO T; IGURA T; DOI Y; MATSUZAWA Y
    RECOMBINANT INTERFERON-ALPHA-2A FOR TREATMENT OF CHRONIC HEPATITIS-C - RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED DOSE STUDY
    Liver
    
    Y. Imai et al., "RECOMBINANT INTERFERON-ALPHA-2A FOR TREATMENT OF CHRONIC HEPATITIS-C - RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED DOSE STUDY", Liver, 17(2), 1997, pp. 88-92
89. DEB G; JENKNER A; DESIO L; BOLDRINI R; BOSMAN C; STANDOLI N; DONFRANCESCO A
    SPINDLE-CELL (KAPOSIFORM) HEMANGIOENDOTHELIOMA WITH KASABACH-MERRITT SYNDROME IN AN INFANT - SUCCESSFUL TREATMENT WITH ALPHA-2A INTERFERON
    Medical and pediatric oncology
    
    G. Deb et al., "SPINDLE-CELL (KAPOSIFORM) HEMANGIOENDOTHELIOMA WITH KASABACH-MERRITT SYNDROME IN AN INFANT - SUCCESSFUL TREATMENT WITH ALPHA-2A INTERFERON", Medical and pediatric oncology, 28(5), 1997, pp. 358-361
90. NORDOY I; KRARUP HB; BELL H; CHRISTENSEN PB; ELGJO K; VONDERLIPPE B; DEMUCKADELL OS; MAELAND A; RINGLARSEN H; SAMDAL HH; SIMMONDS P; SKAUG K; TAGEJENSEN U; SCHRUMPF E
    INTERFERON-ALPHA-2B THERAPY IN LOW-ACTIVITY HEPATITIS-C - A PILOT-STUDY
    Scandinavian journal of gastroenterology
    
    I. Nordoy et al., "INTERFERON-ALPHA-2B THERAPY IN LOW-ACTIVITY HEPATITIS-C - A PILOT-STUDY", Scandinavian journal of gastroenterology, 32(12), 1997, pp. 1256-1260
91. CHRISTEFF N; GHARAKHANIAN S; THOBIE N; WIRBEL E; DALLE MT; COSTAGLIOLA D; NUNEZ EA; ROZENBAUM W
    EFFECT OF INTERFERON-ALPHA ON HIGH SERUM ANDROGEN CONCENTRATIONS IN HIV-POSITIVE MEN WITH KAPOSIS-SARCOMA
    Journal of Clinical Pathology
    
    N. Christeff et al., "EFFECT OF INTERFERON-ALPHA ON HIGH SERUM ANDROGEN CONCENTRATIONS IN HIV-POSITIVE MEN WITH KAPOSIS-SARCOMA", Journal of Clinical Pathology, 50(4), 1997, pp. 341-345
92. VANDERLEEDE BM; VANDENBRINK CE; PIJNAPPEL WWM; SONNEVELD E; VANDERSAAG PT; VANDERBURG B
    AUTOINDUCTION OF RETINOIC ACID METABOLISM TO POLAR DERIVATIVES WITH DECREASED BIOLOGICAL-ACTIVITY IN RETINOIC ACID-SENSITIVE, BUT NOT IN RETINOIC ACID-RESISTANT HUMAN BREAST-CANCER CELLS
    The Journal of biological chemistry
    
    B.M. Vanderleede et al., "AUTOINDUCTION OF RETINOIC ACID METABOLISM TO POLAR DERIVATIVES WITH DECREASED BIOLOGICAL-ACTIVITY IN RETINOIC ACID-SENSITIVE, BUT NOT IN RETINOIC ACID-RESISTANT HUMAN BREAST-CANCER CELLS", The Journal of biological chemistry, 272(29), 1997, pp. 17921-17928
93. KAWA S; NIKAIDO T; AOKI Y; ZHAI YL; KUMAGAYA T; FURIHATA K; FUJII S; KIYOSAWA K
    AROTINOID MOFAROTENE (RO40-8757) UP-REGULATES P21 AND P27 DURING GROWTH-INHIBITION OF PANCREATIC-CANCER CELL-LINES
    International journal of cancer
    
    S. Kawa et al., "AROTINOID MOFAROTENE (RO40-8757) UP-REGULATES P21 AND P27 DURING GROWTH-INHIBITION OF PANCREATIC-CANCER CELL-LINES", International journal of cancer, 72(5), 1997, pp. 906-911
94. LIPPMAN SM; LOTAN R; SCHLEUNIGER U
    RETINOID-INTERFERON THERAPY OF SOLID TUMORS
    International journal of cancer
    
    S.M. Lippman et al., "RETINOID-INTERFERON THERAPY OF SOLID TUMORS", International journal of cancer, 70(4), 1997, pp. 481-483
95. FORMELLI F; CAVADINI E; MASCHERONI L; BELLI F; CASCINELLI N
    PHARMACOKINETICS AND EFFECTS ON PLASMA RETINOL CONCENTRATIONS OF 13-CIS-RETINOIC ACID IN MELANOMA PATIENTS
    British Journal of Cancer
    
    F. Formelli et al., "PHARMACOKINETICS AND EFFECTS ON PLASMA RETINOL CONCENTRATIONS OF 13-CIS-RETINOIC ACID IN MELANOMA PATIENTS", British Journal of Cancer, 76(12), 1997, pp. 1655-1660
96. DARNOWSKI JW; DAVOL PA; GOULETTE FA
    HUMAN RECOMBINANT INTERFERON ALPHA-2A PLUS 3'-AZIDO-3'-DEOXYTHYMIDINE- SYNERGISTIC GROWTH-INHIBITION WITH EVIDENCE OF IMPAIRED DNA-REPAIR IN HUMAN COLON ADENOCARCINOMA CELLS
    Biochemical pharmacology
    
    J.W. Darnowski et al., "HUMAN RECOMBINANT INTERFERON ALPHA-2A PLUS 3'-AZIDO-3'-DEOXYTHYMIDINE- SYNERGISTIC GROWTH-INHIBITION WITH EVIDENCE OF IMPAIRED DNA-REPAIR IN HUMAN COLON ADENOCARCINOMA CELLS", Biochemical pharmacology, 53(4), 1997, pp. 571-580
97. EUVRARD S; KANITAKIS J; THIVOLET J; CLAUDY A
    RETINOIDS FOR THE MANAGEMENT OF DERMATOLOGICAL COMPLICATIONS OF ORGAN-TRANSPLANTATION
    Biodrugs
    
    S. Euvrard et al., "RETINOIDS FOR THE MANAGEMENT OF DERMATOLOGICAL COMPLICATIONS OF ORGAN-TRANSPLANTATION", Biodrugs, 8(3), 1997, pp. 176-184
98. DMITROVSKY E
    N-(4-HYDROXYPHENYL)RETINAMIDE ACTIVATION OF A DISTINCT PATHWAY SIGNALING APOPTOSIS
    Journal of the National Cancer Institute
    
    E. Dmitrovsky, "N-(4-HYDROXYPHENYL)RETINAMIDE ACTIVATION OF A DISTINCT PATHWAY SIGNALING APOPTOSIS", Journal of the National Cancer Institute, 89(16), 1997, pp. 1179-1181
99. LANVERS C; HEMPEL G; BLASCHKE G; BOOS J
    SIMULTANEOUS DETERMINATION OF ALL-TRANS-RETINOIC, 13-CIS-RETINOIC AND9-CIS-RETINOIC ACID, THEIR 4-OXO METABOLITES AND ALL-TRANS-RETINOL INHUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    Journal of chromatography B. Biomedical applications
    
    C. Lanvers et al., "SIMULTANEOUS DETERMINATION OF ALL-TRANS-RETINOIC, 13-CIS-RETINOIC AND9-CIS-RETINOIC ACID, THEIR 4-OXO METABOLITES AND ALL-TRANS-RETINOL INHUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY", Journal of chromatography B. Biomedical applications, 685(2), 1996, pp. 233-240
100. QUAN WDY; CASAL R
     WEEKLY 5-FLUOROURACIL AND INTERFERON-ALFA-2B IN METASTATIC CANCER
     CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
     
     W.D.Y. Quan e R. Casal, "WEEKLY 5-FLUOROURACIL AND INTERFERON-ALFA-2B IN METASTATIC CANCER", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(3), 1996, pp. 187-191